By Scientia Professor Vlado Perkovic

Journal articles

LI J; JARDINE MJ; NEAL B; HEERSPINK HL; CANNON C; AGARWAL R; BAKRIS G; CHARYTAN DM; ZEEUW DD; EDWARDS R; GREENE TOM; LEVIN A; POLLOCK CA; ROSENTHAL N; WHEELER DC; ZHANG H; ZINMAN B; PERKOVIC V; MAHAFFEY KW; ARNOTT C, 2020, '27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease', Diabetes, 69, http://dx.doi.org/10.2337/db20-27-or

Tuttle K; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa140.mo051

Kang A; Neuen B; Heerspink HL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M; Lambers Heerspink H, 2020, 'P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1013, http://dx.doi.org/10.1093/ndt/gfaa142.p1013

Kang A; Smyth B; Neuen B; Lambers Heerspink H; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M, 2020, 'P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa142.p1019

Young T; Li J-W; Kang A; Heerspink H; Hockham C; Arnott C; Neuen B; Zoungas S; Mahaffey KW; Perkovic V; De Zeeuw D; Fulcher G; Neal B; Jardine M, 2020, 'P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1028, http://dx.doi.org/10.1093/ndt/gfaa142.p1028

Smyth B; Chan CT; Grieve SM; Puranik R; Zuo L; Hong D; Gray NA; De Zoysa JR; Scaria A; Gallagher M; Perkovic V; Jardine M, 2020, 'Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis', Journal of Cardiac Failure, 26, pp. 482 - 491, http://dx.doi.org/10.1016/j.cardfail.2020.03.010

Tuttle K; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa141.to002

Arnott C; Huang Y; Neuen BL; Di Tanna GL; Cannon CP; Oh R; Edwards R; Kavalam M; Rosenthal N; Perkovic V; Jardine MJ; Mahaffey K; Neal B, 2020, 'The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.', Diabetes Obes Metab, 22, pp. 1753 - 1766, http://dx.doi.org/10.1111/dom.14091

Torda A; Perkovic V; Velan G, 2020, 'The impact of COVID-19 pandemic on medical education', Medical Journal of Australia, 213, pp. 188 - 188.e1, http://dx.doi.org/10.5694/mja2.50705

Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; De Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V, 2020, 'Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial', Journal of the American Society of Nephrology, 31, pp. 1128 - 1139, http://dx.doi.org/10.1681/ASN.2019111168

Ohkuma T; Van Gaal L; Shaw W; Mahaffey KW; de Zeeuw D; Matthews DR; Perkovic V; Neal B, 2020, 'Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 530 - 539, http://dx.doi.org/10.1111/dom.13920

Inagaki N; Yang W; Watada H; Ji L; Schnaidt S; Pfarr E; Okamura T; Johansen OE; George JT; von Eynatten M; Rosenstock J; Perkovic V; Wanner C; Cooper ME; Alexander JH; Komuro I; Nangaku M, 2020, 'Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA^® trial', Diabetology International, 11, pp. 129 - 141, http://dx.doi.org/10.1007/s13340-019-00412-x

Cannon CP; Perkovic V; Agarwal R; Baldassarre J; Bakris G; Charytan DM; De Zeeuw D; Edwards R; Greene T; Heerspink HJL; Jardine MJ; Levin A; Li JW; Neal B; Pollock C; Wheeler DC; Zhang H; Zinman B; Mahaffey KW, 2020, 'Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial', Circulation, 141, pp. 407 - 410, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044359

Arnott C; Li Q; Kang A; Neuen BL; Bompoint S; Lam CSP; Rodgers A; Mahaffey KW; Cannon CP; Perkovic V; Jardine MJ; Neal B, 2020, 'Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis', Journal of the American Heart Association, 9, pp. e014908, http://dx.doi.org/10.1161/JAHA.119.014908

Li JW; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B, 2020, 'Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes', JACC: Heart Failure, 8, pp. 57 - 66, http://dx.doi.org/10.1016/j.jchf.2019.08.004

Neuen BL; Perkovic V, 2020, 'Pilot trials in nephrology: Establishing a base for large-scale randomized trials', Journal of the American Society of Nephrology, 31, pp. 4 - 6, http://dx.doi.org/10.1681/ASN.2019111196

Heerspink HJL; Oshima M; Jardine MJ; Agarwal R; Bakris GL; Cannon CP; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; Neal B; Pollock CA; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Perkovic V, 2020, 'Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE', Journal of the American Society of Nephrology, 31, pp. 342 - 343, http://dx.doi.org/10.1681/asn.20203110s1342b

Sen T; Li J; Neuen BL; Parikh CR; Coca SG; Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Hansen MK; Heerspink HJL, 2020, 'Associations Between TNFR-1, TNFR-2, and KIM-1 with Kidney and Cardiovascular Outcomes: Results from the CANVAS Trial', Journal of the American Society of Nephrology, 31, pp. 338 - 338, http://dx.doi.org/10.1681/asn.20203110s1338c

Neuen BL; Yu J; Li Q; Perkovic V; Arnott CG; Neal B; Heerspink HJL; Agarwal R; Bakris GL; Cannon CP; de Zeeuw D; Charytan DM; Levin A; Di Tanna GL; Matthews DR; Pollock CA; Wheeler DC; Mahaffey KW; Jardine MJ, 2020, 'Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE', Journal of the American Society of Nephrology, 31, pp. b6 - b6, http://dx.doi.org/10.1681/asn.20203110s1b6a

Kang A; Neuen BL; Heerspink HJL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris GL; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock CA; Wheeler DC; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ, 2020, 'Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343c

Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris GL; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock CA; Wheeler DC; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ, 2020, 'Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344a

Rasmussen DGK; Jatkoe T; Sparding N; Mϕller AL; Karsdal MA; Rosenthal N; Gutstein DE; Neal B; Perkovic V; Mahaffey KW; Genovese F; Hansen MK, 2020, 'Canagliflozin Treatment Reduces Formation and Increases Degradation of Collagen Type III in the Canagliflozin Cardiovascular Assessment Study (CANVAS)', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343b

Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock CA; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL, 2020, 'Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344b

Levin A; Neuen BL; Mahaffey KW; Cannon CP; Jardine MJ; Heerspink HJL; Neal B; Arnott CG; Zhou Z; Charytan DM; Agarwal R; Bakris GL; de Zeeuw D; Greene T; Wheeler DC; Rosenthal N; Zhang H; Zinman B; Perkovic V; Pollock CA, 2020, 'Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 342 - 342, http://dx.doi.org/10.1681/asn.20203110s1342a

Young TK; Li J; Kang A; Heerspink HJL; Hockham C; Arnott CG; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine MJ, 2020, 'Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344c

Tuttle KR; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials', Journal of the American Society of Nephrology, 31, pp. 349 - 350, http://dx.doi.org/10.1681/asn.20203110s1349c

Cherney D; Hadjadj S; Idorn T; Mosenzon O; Pilemann-Lyberg S; Perkovic V; Tuttle KR; Rasmussen S; Bain SC, 2020, 'Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs', Journal of the American Society of Nephrology, 31, pp. 349 - 349, http://dx.doi.org/10.1681/asn.20203110s1349b

Tuttle KR; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6', Journal of the American Society of Nephrology, 31, pp. 36 - 36, http://dx.doi.org/10.1681/asn.20203110s136a

Bakris GL; Jardine MJ; Zhou Z; Heerspink HJL; Li Q; Agarwal R; Charytan DM; Oh R; Pollock CA; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2020, 'Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis', Journal of the American Society of Nephrology, 31, pp. 328 - 328, http://dx.doi.org/10.1681/asn.20203110s1328a

Perkovic V; Bakris GL; Blais J; Cherney D; Damaraju C; Gogate J; Heerspink HJL; Kosiborod M; Mahaffey KW, 2020, 'Risk of Hospitalization for Heart Failure (HHF) by eGFR and Urinary Albumin-to-Creatinine Ratio (UACR): Pooled Analyses from the CANVAS Program and CREDENCE', Journal of the American Society of Nephrology, 31, pp. 335 - 335, http://dx.doi.org/10.1681/asn.20203110s1335c

Jardine M; Zhou Z; Heerspink HJL; Li Q; Agarwal R; Bakris G; Charytan DM; Oh R; Pollock C; Wheeler DC; Zeeuw DD; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2020, 'SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS', Kidney International Reports, 5, pp. S67 - S67, http://dx.doi.org/10.1016/j.ekir.2020.02.166

Liyanage T; Toyama T; Ninomiya T; Perkovic V; Woodward M; Fukagawa M; Matsushita K; Praditpornsilpa K; Seong HL; Iseki K; Lin MY; Stirnadel-Farrant HA; Jha V; Jun M, 2020, 'SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA – A SYSTEMATIC REVIEW AND ANALYSIS', Kidney International Reports, 5, pp. S245 - S245, http://dx.doi.org/10.1016/j.ekir.2020.02.634

OSHIMA M; Wong MG; Hara A; Toyama T; Jun M; Jardine M; Pollock C; Woodward M; Chalmers J; Perkovic V; Wada T, 2020, 'SUN-161 CIRCULATING AUTOANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES', Kidney International Reports, 5, pp. S267 - S267, http://dx.doi.org/10.1016/j.ekir.2020.02.690

Tiku A; Pascoe E; Boudville N; Cass A; Dalbeth N; Day RO; de Zoysa J; Douglas B; Faull R; Harris D; Hawley C; Jones GR; Kanellis J; Palmer S; Perkovic V; Rangan G; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW; Badve S, 2020, 'The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial', Journal of the American Society of Nephrology, 31, pp. 228 - 229, http://dx.doi.org/10.1681/asn.20203110s1228d

Tiku A; Pascoe E; Boudville N; Cass A; Dalbeth N; Day RO; de Zoysa J; Douglas B; Faull R; Harris D; Hawley C; Jones GR; Kanellis J; Palmer S; Perkovic V; Rangan G; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW; Badve S, 2020, 'The Effects of Allopurinol on the Progression of CKD According to Baseline Serum Urate Level: Results from Post Hoc Analyses of the CKD-FIX Trial', Journal of the American Society of Nephrology, 31, pp. 223 - 223, http://dx.doi.org/10.1681/asn.20203110s1223a

Arnott C; Li J-W; Cannon CP; Neuen B; Heerspink HL; Neal B; Charytan DM; Agarwal R; Bakris GL; De Zeeuw D; Greene T; Levin A; Pollock C; Chang T; Rosenthal N; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey K, 2020, 'THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL', Journal of the American College of Cardiology, 75, pp. 674, http://dx.doi.org/10.1016/s0735-1097(20)31301-2

Sen T; Li J; Neuen BL; Neal B; Parikh CR; Coca SG; Perkovic V; de Zeeuw D; Mahaffey KW; Hansen MK; Heerspink HJL, 2020, 'The SGLT2 Inhibitor Canagliflozin Reduces the Plasma Markers TNFR-1, TNFR-2, and KIM-1 in the CANVAS Trial', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343a

Smyth B; van den Broek-Best O; Hong D; Howard K; Rogers K; Zuo L; Gray NA; de Zoysa JR; Chan CT; Lin H; Zhang L; Xu J; Cass A; Gallagher M; Perkovic V; Jardine M, 2019, 'Varying association of extended hours dialysis with quality of life', Clinical Journal of the American Society of Nephrology, 14, pp. 1751 - 1762, http://dx.doi.org/10.2215/CJN.06800619

Li JW; Badve SV; Zhou Z; Rodgers A; Day R; Oh R; Lee M; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Matthews DR; Neal B, 2019, 'The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program', The Lancet Rheumatology, 1, pp. e220 - e228, http://dx.doi.org/10.1016/S2665-9913(19)30078-5

Smyth B; Trongtrakul K; Haber A; Talbot B; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review', BMJ Global Health, 4, pp. e001940, http://dx.doi.org/10.1136/bmjgh-2019-001940

Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ, 2019, 'SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis', The Lancet Diabetes and Endocrinology, 7, pp. 845 - 854, http://dx.doi.org/10.1016/S2213-8587(19)30256-6

Oshima M; Jun M; Ohkuma T; Toyama T; Wada T; Cooper ME; Hadjadj S; Hamet P; Harrap S; Mancia G; Marre M; Williams B; Chalmers J; Woodward M; Perkovic V, 2019, 'The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study', Diabetologia, 62, pp. 1988 - 1997, http://dx.doi.org/10.1007/s00125-019-4948-4

Neuen BL; Cherney DZ; Jardine MJ; Perkovic V, 2019, 'Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering', CMAJ, 191, pp. E1128 - E1135, http://dx.doi.org/10.1503/cmaj.190047

Perkovic V, 2019, 'Blood pressure: at what level is treatment worthwhile? (vol 42, pg 127, 2019)', AUSTRALIAN PRESCRIBER, 42, pp. 175 - 175, http://dx.doi.org/10.18773/austprescr.2019.062

Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B, 2019, 'Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program', Diabetologia, 62, pp. 1854 - 1867, http://dx.doi.org/10.1007/s00125-019-4955-5

Marx N; McGuire DK; Johansen O; Rosenstock J; Kahn SE; Cooper ME; Toto R; Wanner C; Pfarr E; Schnaidt SY; George JT; Von Eynatten M; Perkovic V; Zinman B; Alexander JA, 2019, 'P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease', European Heart Journal, 40, http://dx.doi.org/10.1093/eurheartj/ehz746.0871

Gray NA; Zuo L; Hong D; Smyth B; Jun M; De Zoysa J; Vo K; Howard K; Wang J; Lu C; Liu Z; Cass A; Perkovic V; Jardine M, 2019, 'Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial', Nephrology, 24, pp. 1056 - 1063, http://dx.doi.org/10.1111/nep.13530

Smyth B; Haber A; Trongtrakul K; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis', JAMA Internal Medicine, 179, pp. 1316 - 1324, http://dx.doi.org/10.1001/jamainternmed.2019.1501

Jardine MJ; Mahaffey KW; Perkovic V, 2019, 'Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply', The New England journal of medicine, 381, pp. 1089 - 1090, http://dx.doi.org/10.1056/NEJMc1909687

Inker LA; Heerspink HJL; Tighiouart H; Levey AS; Coresh J; Gansevoort RT; Simon AL; Ying J; Beck GJ; Wanner C; Floege J; Li PKT; Perkovic V; Vonesh EF; Greene T, 2019, 'GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials', Journal of the American Society of Nephrology, 30, pp. 1735 - 1745, http://dx.doi.org/10.1681/ASN.2019010007

Back to profile page